GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln
British drugmaker GlaxoSmithKline Plc
will invest $250 million in Vir Biotechnology Inc
and collaborate to develop potential treatments for
COVID-19, the disease caused by the new coronavirus, the
companies said on Monday.
will invest $250 million in Vir Biotechnology Inc
and collaborate to develop potential treatments for
COVID-19, the disease caused by the new coronavirus, the
companies said on Monday.
Posted by Reuters
